Edition:
United States

RaQualia Pharma Inc (4579.T)

4579.T on Tokyo Stock Exchange

422JPY
2:00am EDT
Change (% chg)

¥6 (+1.44%)
Prev Close
¥416
Open
¥415
Day's High
¥423
Day's Low
¥415
Volume
293,400
Avg. Vol
159,844
52-wk High
¥654
52-wk Low
¥308

Latest Key Developments (Source: Significant Developments)

RaQualia Pharma to fully acquire TMRC via stock swap
Monday, 26 Dec 2016 01:33am EST 

RaQualia Pharma Inc <4579.T> : Says RaQualia Pharma enters into agreement to fully acquire TMRC Co Ltd which is engaged in anticarcinogen related business, through stock swap, with effective date on Feb. 3, 2017 . One share of TMRC's stock will be exchanged with 90 shares of co's stock .479,250 shares of co's stock will be exchanged.  Full Article

RaQualia Pharma gets substance patent for ghrelin receptor agonist(serine derivative) in Japan
Thursday, 6 Oct 2016 12:14am EDT 

RaQualia Pharma Inc <4579.T>: Says it received substance patent for ghrelin receptor agonist(serine derivative) in Japan .Says the substance is used for improvement of anorexia and suppression of body weight reduction.  Full Article

RaQualia Pharma gets sodium channel blocker patent allowance in China
Thursday, 22 Sep 2016 11:01pm EDT 

RaQualia Pharma Inc <4579.T>:Says it received an allowance for sodium channel blocker substance patent in China (Application No.201380022248.1).  Full Article

RaQualia Pharma says sodium channel blocker patent allowance in China
Monday, 25 Jul 2016 02:12am EDT 

RaQualia Pharma Inc <4579.T>:Says the company received an allowance for a sodium channel blocker substance patent in China (Application Number: 201180050306.2, Arylamide derivatives).  Full Article

RaQualia Pharma receives patent recognition for sodium channel blocker from EU
Thursday, 7 Jul 2016 02:17am EDT 

RaQualia Pharma Inc <4579.T>: Says it received patent recognition for its sodium channel blocker from Europe .Says sodium channel blocker is a medicine used to relieve the pain.  Full Article

RaQualia Pharma gets FDA approval
Wednesday, 18 May 2016 03:28am EDT 

RaQualia Pharma Inc <4579.T>: Says the company received approval for Entyce from the U.S. Food and Drug Administration (FDA) in U.S. on May 17 .Says Entyce is for the treatment of dogs' anorexia.  Full Article

RaQualia Pharma says patent assessment for 5-HT2B antagonist in Korea
Wednesday, 20 Apr 2016 02:00am EDT 

RaQualia Pharma Inc:Says received decision for a patent grant to 5-HT2B antagonist in Korea.Says 5-HT2B receptors are widely distributed through-out the human intestinal tract and are thought to be a viable new target for irritable bowel syndrome (IBS) treatment.  Full Article

RaQualia Pharma enters joint research agreement with ASAHI KASEI PHARMA
Monday, 21 Mar 2016 10:30pm EDT 

RaQualia Pharma Inc:Enters a joint research agreement with ASAHI KASEI PHARMA CORPORATION on March 22.Says the two entities to be engaged in joint research of new pharmaceuticals which take the specified ion channels as target.  Full Article

RaQualia Pharma announces result of early-retirement program
Thursday, 24 Dec 2015 01:30am EST 

RaQualia Pharma Inc:Says 8 employees took up the offer of the early-retirement program announced on Nov. 30.Effective date of retirement is Jan. 31, 2016.A premium will be added to the normal retirement allowance of eligible applicants.Says eligible applicants will also have the option to receive job-placement assistance.  Full Article

RaQualia Pharma announces business alliance with XuanZhu Pharma
Tuesday, 22 Dec 2015 03:45am EST 

RaQualia Pharma Inc:Announced a business alliance with China-based company XuanZhu Pharma Co.,Ltd.Says two entities will cooperate on creation of new analgesic.  Full Article

More From Around the Web

BRIEF-RaQualia Pharma gets substance patent for ghrelin receptor agonist(serine derivative) in Japan

* Says it received substance patent for ghrelin receptor agonist(serine derivative) in Japan